Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-5573a in Japanese patients with advanced solid tumors
NCT02192567Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2014
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS-5573a in solid tumor (advanced stage), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose Limiting Toxicities, Adverse Events and 1 more. Started Sep 2014; status: terminated.
02
Drugs
DS-5573a
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02192567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192567.